The short answer
Native GLP-1 acts largely on receptors sitting on vagal afferent nerve endings close to where it is released. Knocking those receptors down in rats increased meal size and accelerated gastric emptying, while leaving long-term energy balance under normal eating intact.
Key facts
- Receptor location
- Vagal afferent neurons, nodose ganglion
- Native GLP-1 circulating half-life
- Minutes, cleaved by DPP-4
- Knockdown effect on meal size
- Increased
- Knockdown effect on gastric emptying
- Accelerated
- Knockdown effect on postmeal glycaemia
- Elevated
- Knockdown effect on insulin release
- Blunted
- Knockdown effect on long-term energy balance
- None under normal eating
- Term used by the authors
- Neuroincretin effect
Why the route matters more than it sounds
Native GLP-1 is destroyed within minutes of release by DPP-4, and a substantial fraction is cleaved before it even leaves the intestinal circulation. That creates a problem for the textbook picture of a hormone travelling through the bloodstream to distant targets: for most of what GLP-1 does physiologically, not enough of it survives the journey. The resolution is that much of its action is local. GLP-1 receptors sit on the terminals of vagal afferent nerves in the gut wall, close to where the hormone is released, and signalling through those terminals reaches the brainstem as nerve traffic rather than as circulating peptide.
The knockdown experiment
Krieger and colleagues knocked down GLP-1 receptors specifically on vagal afferent neurons in rats and measured what changed. Three things did. Meal size increased. Gastric emptying accelerated. Postmeal glycaemia was elevated and insulin release was blunted, which the authors describe as evidence that these receptors are physiological contributors to what they call the neuroincretin effect after a meal. That is a coherent picture of a within-meal control system: the gut detects nutrients, releases GLP-1 locally, the vagus reports it, and the response slows gastric emptying, limits the meal and primes insulin release.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
And the thing that did not change
Long-term energy balance. The authors state that a full expression of vagal afferent GLP-1 receptors is not necessary for the maintenance of long-term energy balance under normal eating conditions. Removing most of the receptors through which native GLP-1 acts did not make the animals fat. That is the single most important sentence in this literature for anyone trying to reason about what GLP-1 drugs do, and it is almost never quoted.
What it implies about the drugs
If native GLP-1 signalling through its principal physiological route does not set body weight, then a drug that does set body weight is not doing so by restoring or amplifying that route. The pharmacological agents differ from the hormone in three ways at once: they resist DPP-4, so they survive to circulate; they are engineered to persist for days rather than minutes, so exposure is continuous rather than postprandial; and continuous circulating exposure reaches central GLP-1 receptors that a locally released, rapidly degraded hormone largely does not. The drug is not a bigger dose of the physiology. It engages a different part of the system, continuously, at concentrations the body never produces.
A related finding about synergy
Iwasaki and colleagues recorded from nodose ganglion neurons and found that GLP-1 and insulin synergistically activate vagal afferents. Responses to GLP-1 were blocked by the antagonist exendin(9-39), confirming they were receptor-mediated, and 92% of GLP-1-responsive neurons also responded to insulin. At low concentrations of each, neither did much alone, but the two in combination recruited previously unresponsive neurons and produced larger responses in responsive ones. That is a plausible mechanism for how two postprandial signals arriving together are read as more than either alone, and it is a reminder that these afferents integrate rather than simply relay.
How to use this when reading a claim
Any statement of the form 'this raises your natural GLP-1' is a claim about the pathway described here: local release, rapid degradation, vagal signalling, within-meal effects. It is not a claim about the pathway a GLP-1 receptor agonist engages, and the knockdown result indicates the two are not on the same continuum with respect to body weight. Licensed GLP-1 receptor agonists are prescription medicines; nothing supplied on this site is a version of one, an alternative to one, or a way of achieving what one achieves.
Frequently asked questions
Does this mean native GLP-1 does not affect appetite?
It affects meal size, which is an appetite effect within a meal. What the knockdown showed is that removing the receptors did not disturb long-term energy balance in normally eating animals, a statement about body weight over time, not about within-meal satiation.
Do GLP-1 drugs work through the vagus too?
Partly, and the relative contribution of vagal and direct central routes is still argued. The point of the knockdown result is that the vagal route alone does not account for sustained weight change, which is what the drugs produce.
Why is exendin(9-39) used to confirm the response?
It is a GLP-1 receptor antagonist. If a response disappears when the receptor is blocked, the response was mediated by that receptor rather than by something incidental. The same logic as a knockout, applied pharmacologically and reversibly.
Was the knockdown complete?
No, and the authors are careful about this: it was a knockdown rather than a knockout, so residual receptor expression remained. That makes the positive findings, meal size, gastric emptying, glycaemia,robust, and means the absence of a long-term weight effect should be read as an absence under partial reduction.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedKrieger JP et al., Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia - Diabetes 2016 (PMID 26470787)pubmed.ncbi.nlm.nih.gov
- PubMedIwasaki Y et al., Glucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons - Neuropeptides 2017 (PMID 28624122)pubmed.ncbi.nlm.nih.gov
- PubMedReimann F, Gribble FM, Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion - J Diabetes Investig 2016 (PMID 27186350)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Why Where Bile Arrives Changes How Much GLP-1 Comes OutBile acids are signalling molecules as well as detergents. They act on a receptor on L cells, and delivering them further down the gut raises the response.
- Two Nearly Identical Cells Releasing Opposite-Tempered HormonesGIP and GLP-1 come from different cells that are transcriptomically close and share a glucose sensor. The differences between them are small but exploitable.
- The Gap Between a Meal Response and a DrugNative GLP-1 is released in bursts and destroyed within minutes. An agonist is present continuously for a week or more. The difference is not one of degree.
- The Randomisation Ratio Decides What a Trial Can SayTwo trials of the same combination allocated participants very differently. One can measure the components' contribution properly and the other cannot.
- A p-Value of 0.0035 and an Effect of 0.16A large trial can detect a difference far below the size that would matter to anyone. Statistical significance and clinical importance are separate questions.